MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Regulatory/Compliance / Food & Drug Administration (FDA) / Kips Bay Medical shares reach new low on FDA setback for surgical mesh

Kips Bay Medical shares reach new low on FDA setback for surgical mesh

September 22, 2011 By MassDevice staff Leave a Comment

Kips Bay

Kips Bay Medical Inc. (NSDQ:KIPS) shares sank hard and fast on news that the FDA asked for additional information before allowing its eSVS surgical mesh to undergo clinical testing.

The Minneapolis-based company lost 34 percent yesterday, closing at $1.87 (compared to a close of $2.85 on Sept. 20). Along the way, shares hit an all-time low of $1.79.

Kips’ eSVS surgical mesh, a flexible device used to strengthen vein grafts during coronary artery bypass procedures, is under consideration for an investigational device exemption to begin conducting clinical trials toward U.S. marketing clearance. The FDA told the company that it needs to provide more data to support its application, according to a press release.

"While we are disappointed with the news from the FDA, we remain confident that our European studies will demonstrate the improved patency of grafts treated with the eSVS Mesh as compared to untreated grafts," chairman and CEO Manny Villafana said in prepared remarks. "We will then present this data to the FDA as further evidence supporting our request for an IDE."

The company is pursuing clinical studies in Europe and the United Arab Emirates in hopes of obtaining the necessary data to satisfy IDE status for the FDA.

Kips Bay stock has plummeted 78 percent since February, when it hit a high-water mark of $8.37 shortly after launching an initial public offering, which opened at $8.00 and raised $17 million on a hoped-for $21.2 million offering.

Shares have dropped pretty steadily since then, hitting the halfway mark of $4.00 by mid-May as sales of the company’s flagship mesh device have lagged.

The eSVS device won CE Mark in the European Union in May 2010, but sales have lagged.

"[W]e have not generated significant revenue from the sale of products to date," the company wrote in the Jan. 18, 2011, filing.

Kips managed to narrow losses heavily in the three months ended July 2, 2011, reporting $1.04 million lost, 82 percent less than the $5.9 million lost during the same period in 2010. Sales remained steady at $48,000 compared to last year.

Filed Under: Food & Drug Administration (FDA), News Well, Surgical, Wall Street Beat Tagged With: Clinical Trials, Kips Bay Medical Inc.

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS